SREBF1 and colorectal carcinoma: All of these above data support our findings that ACM treatment could induce SREBP-1 mRNA and protein expressions and subsequently reduce the sensitivity of 5-FU cytotoxicity in both human DLD-1 and SW480 CRC cells.